Table 1 Patients’ demographic and clinical characteristics
Patients (n) | 789 |
Age at diabetes diagnosis (years) | 53.3 ± 10.5 |
Sex (male/female) | 373/416 |
Smoking (none/former/current) | 598/45/146 |
Hypertension (%) | 597 (75.7) |
Hyperlipidemia (%) | 758 (96.1) |
Body mass index (kg/m2) | 26.8 ± 3.9 |
Mean number of measurements | 45.0 ± 24.5 |
Mean SBP (mmHg) | 137 ± 10 |
Mean number of measurement | 63.0 ± 28.9 |
SD of SBP (mmHg) | 14.7 ± 3.6 |
Delta SBP (mmHg) | 71.7 ± 25.0 |
Mean DBP (mmHg) | 73.5 ± 6.3 |
SD of DBP (mmHg) | 7.4 ± 2.0 |
Delta DBP (mmHg) | 37.7 ± 14.3 |
Hemoglobin A1c (%) (mmol/mol) | 7.6 ± 1.0 (60.0 ± 10.9) |
Mean number of measurements | 34.8 ± 10.9 |
Total cholesterol (mg/dL) | 193.4 ± 28.6 |
Mean number of measurements | 11.9 ± 5.8 |
High-density lipoprotein (mg/dL) | 38.5 ± 10.7 |
Low-density lipoprotein (mg/dL) | 118.7 ± 20.3 |
Triglyceride (mg/dL) | 149.8 ± 113.8 |
Initial eGFR (mL/min/1.73 m2) | 88.6 ± 22.7 |
Mean number of measurements | 17.9 ± 6.7 |
Final eGFR (mL/min/1.73 m2) | 75.1 ± 27.6 |
Clinical Events during10-year follow-up | |
CVD a (%) | 115 (14.6) |
Interval from diabetes diagnosis (years) | 5.2 ± 3.1 |
Change in CKD stage | 1.2 ± 0.7 |
Renal function impairment (%) | 309 (39.2) |
CKD stage 4 or 5 (%) | 83 (10.5) |
Total follow-up period (days) | 4451 ± 453 |